Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Radds
Assuming your wife is 55+ she could withdraw a lump sum from tax-free cash by crystallising funds (called drawdown) or take it 25% tax free cash 75% taxable (called Uncrystallised Fund Pension Lump Sum).
Drawback of UFPLS is that pension contributions would be limited to £4k gross pa (assuming she has earnings of at least that) or £3,600 gross pa if no earnings.
You cannot access a SIPP before minimum pension age which is currently 55. Anyone offering to do it for you is a scam.
If 1st time accessing the pension it will likely be taxed at emergency rates with any overpayment reclaimable from HMRC which takes a few weeks.
Think I've lulled myself to sleep with that post ??
The FDA granted orphan status based on pre-clinical data. It is no reflection on how well the trial may be going.
As per RNS
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"We are delighted to receive Orphan Drug Designation from the FDA for AVA6000, which is a reflection of the high quality of the preclinical data and the potential benefit the pre|CISION platform can bring to cancer patients.
Is the CT value for the sensitivity given anywhere? Without that the % is impossible to compare to other LFTs.
It needs to detect infectious carriers which is thought to be around CT<25 according to the govt.
Surprised this hasn't had more attention on this board.
It says that DT analysed track and trace info which showed 1/3 of (presumably positive) LFTs came back negative when checked by PCR.
If that's the case (I don't subscribe to DT so only saw the front page on BBC) then Innova's real world specificity is much poorer than claimed by Innova, Porton Down and the Liverpool study.
Based on the Liverpool study Innova has an in the field sensitivity of 57%-79% depending on who's administering the test and specificity of 99.7% (Porton Down) or approx 66% on secondary school kids (Daily Telegraph).
If correct I wonder how much of the drop in performance is due to the EUA allowing it to be AN rather than NP though I would have thought that would more likely affect sensitivity more than specificity?
AS said in the recent 1st vox interview that AVCT are working on demonstrating that the *same* affimer (let alone needing to generate a new affimer) will detect the SA and Brazilian variants.
There's been research done which shows that alot of the variants are developing similar variations independently ie convergent evolution, so the SA, Brazilian and Kent versions share much of the same variations to the same sites on the spike protein.
The fact AVCT's test works on the Kent variant is therefore why AS said he expects the test to work on the newer variants.
Another important point is that the Kent variant appears to be out-competing the SA variant which further bodes well for the s&s.
Whilst I'm hopeful the AVCT test will be more sensitive and crucially more specific than i
Innova's as well as avoid the variance between batches Innova have,
the Innova test was 66% sensitive at ct<25 in Liverpool which was shown to be closer to 75% when the tests were independently checked after the event ie not in the field.
Also half of AVCT samples were at CT 22-26 with the other half presumably <22. Granted the RNS wasn't clear but it wouldn't specify half being at 22-26 if the other half were at 26.
AVCT test is also quicker at 20 minutes vs Innova's 30 and designed to be anterior nasal whereas Innova wasn't originally.
AVCT also works with saliva but seems saliva samples were inconsistent which is presumably why the govt and AVCT prioritised other collection methods.
North East
These are the Innova tests. Basically a US based Chinese businessman's (Weegie educated!) company bought exclusive distribution rights for Xiamen Bio time's tests. They badge them Innova and sell to UK govt for presumably a nice profit.
Due to the Surescreen contract and potentially Mologic and/or Avacta and any others passing govt requirements, Innova will be phased out.
It's crucial the Innova tests are done exactly as per the instructions as in real world use their accuracy reduced from 79% when done by lab scientists to 73% by healthcare workers and 58% when done by the public.
They're an effective way of reducing the R number by identifying people in the most infectious stage which includes pre symptomatic.
These are Innova tests... for now at least. My partner works in early years and took one yesterday she had to pick up from the school.
Before golf
Please check with your sister before posting as some of what you have said she will confirm is incorrect:
Whilst gains in ISAs and pensions are tax free and up to 25% of pensions can be taken tax free, this can be done as often as you like (limited to 25% your lifetime allowance of £1,073,100) as tax free cash hasn't had to have been taken in one go for many years.
An annuity can but doesn't have to be purchased - the non tax free cash ie taxable funds can remain invested (aka in drawdown) and would also have the benefit of not being liable for inheritance tax.
ISA withdrawals are entirely tax free but are liable to inheritance tax.
Pension contributions up to £2,880 pa get basic rate tax relief making the contribution £3,600so not all contributions need to be made from earned ie taxable income to be tax efficient :)
Daft, unfortunately the interim results suggest they don't which doesn't bode well, though they could have bid for the LFT tender which would change things somewhat.
IDS has launched a number of products for COVID-19 testing in H1, but revenues from these products have so far not been able to make up for the impact of the decline in the market for routine testing
PL75 "why do you care about a vaccine?"
Apart from markets over-reacting to positive but interim results from the vaccines Avacta have confirmed they will lower the need for testing. Initially most investors here for the LFT rather than the longer term prospects would have thought we had sales by now. The longer it takes the lower potential returns will be from the LFT as vaccinations commence.
Furthermore Alistair made it clear their focus was on the UK market so it will take yet more time to alter that strategy to those countries who haven't already secured vaccines.
Q30: When a vaccine is developed for coronavirus will there still be a demand for saliva testing?
Vaccines are still in development and when the first ones become available it will take a considerable time to vaccinate a significant proportion of the global population before there is an impact on the need for testing. Furthermore, the level of efficacy of any vaccine, and duration of protection afforded, will influence demand for testing in the future. There will also likely be an ongoing, but much reduced need for testing once a global vaccination programme has been successfully completed.
Hani1
CGT is 10% for basic rate taxpayers, 20% for higher/additional rate taxpayers on gains >£12,300 this tax year.
Put in joint names to get 2 allowances or hold in ISA/SIPP so no CGT.
Can offset previous losses potentially.
ISA and SIPP growth is pretty much tax free but SIPPs are liable to income tax on withdrawals above the (up to) 25% tax free cash.
GIAs (trading accounts) gains over £12,300 pa per holder are taxed at 10% for basic rate taxpayers and 20% for higher/additional rate taxpayers.
AIM shares are IHT free after 2 years only if still held at death.
Yes the sona test uses LFD and gold nanorods which they say also have some of the advantages of affimers eg small, 100% specificity, quick to make and increased sensitivity though I haven't found a figure for this yet.
Seems their test will cost more as they project <$50 but they are validating and have manufacturing agreements and a few million pre-orders so they are ahead of Avacta for now.